Pharmaceutical Science Across Greater King's

Symposium meeting on 7 January 2011

B5 Auditorium, Franklin-Wilkins Building
(http://www.kcl.ac.uk/about/campuses/waterloo.html)

- 09:30 - Introduction by Prof Peter Hylands, Institute of Pharmaceutical Science

- 09:35-10:10 - Wolfson Centre for Age Related Diseases:
  - Prof Pat Doherty: *Introduction to Drug Discovery in the Wolfson CARD*
  - Dr Ramin Raouf: *Open innovation: Drug Discovery in partnership with Academia*
  - Dr Jonathan Corcoran: *Lead optimisation of retinoids for the treatment of CNS disorders*

- 10:10-10:40 - Drug Delivery Group, Institute of Pharmaceutical Science:
  - Dr Lee Ann Dailey: *Nanosafety; Nanomedicine at King’s*
  - Dr Stuart Jones: *Chemical solutions to dynamic drug delivery*

- 10:40-11:10 - Department of Pharmacology:
  - Prof Sue Brain: *The Centre of Integrative Biomedicine and working towards sustainability*
  - Dr Stuart Bevan: *MSc in Drug Discovery Skills*

- 11:10-11:40 - Pharmaceutical Biophysics Group, Institute of Pharmaceutical Science
  - Prof Jayne Lawrence: *Pharmaceutical Biophysics: a quick overview*
- Dr Dave Barlow: *Investigation of the structure and membrane interactions of drug and gene delivery systems*
- Dr Richard Harvey: *Membrane lipids and drug resistance in Staphylococci*

- 11:40-12:15 - **Pharmacology & Therapeutics Group, Institute of Pharmaceutical Science:**
  - Prof Clive Page: *From starfish to novel anti-inflammatories*
  - Prof Peter Jenner: *Parkinson's disease - the future of treatment*

- 12:15-13.30 - **Lunch and posters** (first floor restaurant area)

- 13.30-14:00 - **Biomolecular Spectroscopy Centre:**
  - Dr Alex Drake: *The Role of a Biomolecular Spectroscopy Centre in pharmaceutical science*
  - Dr James Mason: *Design of antimicrobial peptides*
  - Professor James McDonnell: *Structure-based design of inhibitors of the IgE network*

- 14:30-15.00 - **Quintiles Drug Research Ltd**
  - Prof Tim Mant: *Early clinical trial facilities*

- 15.00-15:40 - **Chemical Biology Group, Institute of Pharmaceutical Science**
  - Dr Paul Long: *Drugs from the Sea: Sustainable production of chondropsin metabolites sourced from the Great Barrier Reef sponge Ircinia ramosa*
  - Dr Sukhi Bansal: *Hepcidin - A Biomarker for Iron Status*
  - Dr Maya Thanou: *uPAR targeted nanoparticles*
  - Dr Gerd Wagner: *Targeting glycosylation as a therapeutic approach*

- 15.40-16.00 - **Tea**

- 16.00- 16:30 - **Clinical Practice and Medication Use Group, Institute of Pharmaceutical Science**
  - Dr Catherine McKenzie: *Differentiating MDZ oversedation from neurological damage in the critically ill*
  - Prof David Taylor: *Psychotropic Use - prescribing patterns*
Dr Cate Whittlesea: *Improving medication safety - process and manpower*

- **16:30-17.00 - Institute of Psychiatry**
  - Prof Shitij Kapur: *Understanding how antipsychotics work – from receptors to reality*
  - Prof Simon Lovestone: *Biomarkers for Alzheimer's disease*

- **17:00-17:40 - Key note speaker:**
  - Dr Geoffrey Guy, Chairman, GW Pharmaceuticals plc: *A complex pharmaceutical development - Sativex and beyond*

- **17:45-18:00 - Concluding remarks** - Prof Roger Morris, Head, School of Biomedical Sciences

- **18:00 - Drinks** (first floor restaurant area)
Posters (between 12:30-13:30 in the first floor restaurant area):

**Drug Delivery Group, IPS**

- P1 - A. Patel: *Measurement of Solution-State Salbutamol Ion-Pair Interactions*
- P2 - J. Chana: *Dynamic release from lipid nanoparticles for controlled drug delivery to the airways*
- P4 - W. Wild: *Calcium Phosphate nanoparticles for siRNA delivery: current and future prospects*

**Chemical Biology Group, IPS**

- P5 - S. Gehrke: *Towards novel anti-trypanosomal agents*
- P6 - G. Pergolizzi: *Novel NAD derivatives as tools for chemical biology*
- P7 - A. Soltani, S. Bansal, S. Rose, R. Hider and P. Jenner: *Investigation into the physico-chemical properties of the proteasomal specific Inhibitor I PSI*
- P8 - V. Abbate: *Molecularly imprinted hydrogels for the peptide hormone hepcidin prepared by the epitope approach via water-in-oil suspension polymerization under mild conditions*
- P9 - L. Whiley: *Lipidomic Method Development with A View to Application with Alzheimer’s Disease*
- P10 - B. Panaretou: *An example of characterizing the global effect of a drug on eukaryotic physiology: Genomic screening using Saccharomyces cerevisiae reveals vacuolar ATPase as a major determinant in sensitivity to cisplatin*

**Pharmaceutical Biophysics Group, IPS**

- P11 - R. Harvey: *Can the plasma membrane of Staphylococcus aureus inhibit antimicrobial peptide activity?*
• P12 - L. Kudsiova: *Giant Unilamellar Vesicles as Model Endosomal Membranes*

• P13 - N. Chakroun: *Structural investigation of the Prion protein (PrPc) conversion into neurotoxic PrPsc using MD simulations and SAXS*

• P14 - F. Bode: *Physical studies of enzymatically cross-linked fish gelatin networks for tissue repair*

• P15 - H. Afifi: *Biocompatible wormlike micelles as a drug delivery tool*

❖ Pharmacology & Therapeutics Group, IPS

• P16 - P. Long, S. Rose, P. Jenner: *Identification of interacting partners for osteopontin*

• P17 - C. Page, S. Rose, P. Jenner: *Histone deacetylase inhibitors inhibit survival of dopaminergic neuronal cells against toxin-induced cytotoxicity.*

• P18 - L. Broom, S. Rose, P. Jenner: *Osteopontin increases GDNF and BDNF levels and protects against MPP± induced tyrosine hydroxylase cell loss in primary ventral mesencephalic culture.*


• P20 - S. Pitchford: *The role of ADP on platelet chemotaxis and migration through lung tissue in a murine model of allergic inflammation*


• P22 - T. Hirsch, A. Hikima, M.J. Jackson, K Tayarani-Binazir, R. Fisher, S. Rose, P. Jenner: *Nitric oxide synthase inhibition does not reduce priming for dyskinesia by L-DOPA in primate or rodent models of Parkinson's disease*

• P23 - M. Fidanboylu, C. P. Watson, S. A. Thomas: *Transport of the disease marker ADMA in vivo*
- P24 - M. Nandi: *Understanding tetrahydrobiopterin biosynthesis using biophysical and in-vivo approaches*

- P25 - N. Patel: Clinical Pharmaceutics: *The stability of dobutamine in central intravenous additive service (CIVAS) syringes*

- P26 - L. Sanderson, S.A. Thomas: *Comparison of drugs active against stage 1 (blood) and stage 2 (CNS) human African Trypanosomiasis*

- P27 - C. Watson: *Asymmetric dimethylarginine and the human blood-brain barrier*

- P28 - A. Hsu: *Hydrogen Sulphide (H₂S) Donors On Adhesion Molecule Expression*

- P29 - K. Alawi, J. Keeble: *Effects of the Transient Receptor Potential Vanilloid 1 receptor antagonist, SB366791, in thermal nociception and hyperalgesia*

- P30 - A. Morris: *Pharmacological modulation of the zymosan response in the lung on 7th January*

- P31 - M. Malcangio: *Studying the plasticity of the first pain synapse*

- **Clinical Practice & Medication Use, IPS**
  - P32 - A. Sparshatt: *A Naturalistic Evaluation and Audit Database of Agomelatine (NEVADA): Clinical Outcome at Fourteen Months*

  - P33 - T. Cheung, Dave Barlow: *Analysis and the correlation between drug name similarities and the incidence of medication errors in UK hospitals*

  - P34 - R. Dhital, C. Whittlesea, I. Norman, P. Milligan: *Impact of one-day training on community pharmacists' knowledge of alcohol brief intervention.*

- **Pharmacology Department**
  - P35 - A. Aubdool, R. Graepel, S. Brain: *Interactions between TRPA1 and TRPV1 in the peripheral vasculature*
- Wolfson Centre for Age-Related Diseases
  - P36 - S. Duty: Selective activation of the mGlu4 but not mGlu7 group III metabotropic glutamate receptor provides functional neuroprotection in the rat 6-OHDA model of Parkinson’s disease

- Randall Division of Cell and Molecular Biophysics
  - P37 - M. Conte: p38alpha auto-activation by TAB1. An interdisciplinary approach

- Biomolecular Spectroscopy Centre /NMR centre
  - P39 - A. Atkinson: Centre for Biomolecular Spectroscopy - NMR Facility

- MRC & Asthma UK Centre
  - P40 - A. Beavil: Progress towards small molecule inhibitors of the IgE/FcεRI Interaction

- Analytical and Environmental Science Division

- King’s College Hospital NHS Foundation Trust
  - P42 - K. Lansdown: Management of overanticoagulation with warfarin at King’s College Hospital
  - P 43 - G. Cavell, S. Jaffer: FACT: knowledge of antibiotics contraindicated in penicillin allergy can be improved
  - P44 - M. O’Meara, M.P. Cicałese, N. Hadzic, A. Bordugo, G. Mieli-Vergani: Successful Use of Long-Acting Octreotide for Intractable Chronic Gastrointestinal Bleeding in Children
- P45 - C. Eaton, G. Cavell, R. Onatade: *Developing the definition of a reportable prescribing error*

- P46 - R. Onatade, R. Mehta, O. Shallal: *The selection, modification and reliability testing of a tool for rating the significance of pharmacists’ clinical contributions*

- **Guy’s and St Thomas’ NHS Foundation Trust**
  - P47 - C. A. Oborne, J. Philip, E. Stewart: *Reducing interruptions during adult inpatient medication administration*
  - P49 - D. McRobbie, S. Mercer: *Description and Quantification of Ward Based Pharmacy Activity*
  - P50 - C. McKenzie, D. Naughton, G. Davies, D. Treacher: *Extraction and purification of 1-hydroxymidazolam glucuronide from ultrafiltrate*
  - P51 - C. McKenzie, S. Yassin, M. Terblanche: *Sedation and analgesia: early results from a web-based survey of UK practice*
  - P52 - A. Boyle, C. McKenzie, S. Yassin, A. McLuckie, D. Wyncoll: *Outcomes and incidence of bleeding events associated with drotrecogin alfa: a single-centre experience of 440 patients*

- **King’s Business**
  - P53 - J. Elliott, M. Jorgensen: *Creating Commercial Value - King's Business and IPS*

- **Institute of Psychiatry, School of Biomedical Science**
  - P54 - A. Smith: *Differential effects of Methylphenidate and Atomoxetine on brain activation during time discrimination and sustained attention in medication-naïve children with ADHD*